Company name: Elcelyx Therapeutics.
Location: San Diego, California.
Solution/product: Lovidia is a dietary supplement that helps in weight loss; NewMet treats type 2 diabetes.
Money raised: $4 million of a $7 million extension round; filings show it has raised $20 million to date.
How it will be used: To fund clinical trials of Lovidia and NewMet.
Investors: Morganthaler Ventures, Kleiner Perkins Caufiled & Byers, Technology Partners.
Management team: Dr. Alain Baron, president and CEO; Martin Brown, chief business officer; Mark Fineman, vice president of R&D; Mark Wiggins, senior vice president, business development.
Competitors: Eli Lilly, Novo Nordisk, GSK — diabetes; Vivus, Arena Pharmaceuticals — weight loss drugs.
[Photo Credit: Freedigitalphotos.net]